Bengaluru-based Cureous Labs Bags Seed Funding Led by Inflection Point Ventures

The startup plans to launch its first disinfection center, expand its sales and business development team, and secure essential product safety certifications.

Bengaluru-based medtech startup Cureous Labs has raised ₹16.6 cr in a seed funding round led by Inflection Point Ventures (IPV), with participation from Anthill Ventures.

The fresh capital will be deployed to produce the first batch of its flagship automated patient-turning bed, Eturnal. The startup also plans to launch its first disinfection center, expand its sales and business development team, and secure essential product safety certifications.

Founded in 2020 by Asish Mohandas, Cureous Labs originated from the Biodesign program at AIIMS and IIT Delhi. Mohandas’s mission is to prevent bedsores and reduce caregiver strain through innovative, accessible medical devices.

Vinay Bansal, founder of IPV, said, “Prevention is better than cure, and Cureous Labs is making it affordable and accessible.”

The startup has also secured grants and support from BIRAC, MeitY, the Gates Foundation, Social Alpha, and the SBI Foundation, further validating its impact-focused innovations.

Cureous Labs’ Offerings

The company’s product, Eturnal, automatically repositions bedridden patients to prevent pressure injuries without disturbing medical lines.

Further, Eturnal can retrofit onto standard hospital and home beds, making it available at roughly one-fifth the price of global alternatives.

“At Cureous, our mission is to create technologies that empower independent living. Eturnal, our one-of-a-kind automated patient turning solution, helps prevent pressure injuries while reducing caregiver dependency and effort. We aim to build a portfolio of solutions for geriatric and long-term care. IPV’s early belief in our vision gives us the confidence and resources to scale Cureous into a category-defining company in this space,” said Mohandas.

Cureous Labs reports over 30,000 hours of device use and more than 14,000 patient turns.

It is currently running pilots in both hospital and home-care settings across South India, targeting India’s $8.3 Bn elderly care market.

Mohandas envisions Cureous Labs as a category leader in long-term care technology. Beyond scaling Eturnal, the company plans to build a portfolio of geriatric care solutions, expand its disinfection services, and deepen its reach across India.

Stay tuned for more such updates on Digital Health News